Insider Sells 15% of Arcutis Stake via Trading Plan

On June 15, 2026, Sue-Jean Lin, a director at Arcutis Biotherapeutics (NASDAQ:ARQT), disclosed the sale of 4,946 shares of common stock. The transaction, valued at $24.38 per share, amounted to a total of $705,163.86.

This sale represented a substantial 15% reduction in Lin's direct ownership, decreasing her holdings from 32,513 shares to 27,567 shares. Following the transaction, Lin has no reported indirect or derivative holdings, with her investment exposure limited to her directly held shares.

Notably, the sale was conducted under a 10b5-1 trading plan adopted on December 4, 2025. This indicates the disposition was pre-scheduled and routine, rather than discretionary. This open-market sale is Lin's only one in the past two years; prior transactions were administrative.

Arcutis Biotherapeutics focuses on developing and marketing topical therapies for dermatological conditions. Their portfolio includes roflumilast cream for psoriasis and atopic dermatitis, with other pipeline assets targeting related indications. The company generates revenue through its dermatology treatments and targets healthcare providers in the U.S. and internationally.